ImmunoPrecise Antibodies Ltd. Cash Flow-to-Debt Ratio
ImmunoPrecise Antibodies Ltd. cash flow-to-debt ratio. ImmunoPrecise Antibodies Ltd. (HYFT) has a Cash Flow-to-Debt Ratio of -0.34x as of October 2025, meaning its operating cash flow of $-2.87 Million could theoretically repay 0% of its total liabilities ($8.40 Million) in one year. Check ImmunoPrecise Antibodies Ltd. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ImmunoPrecise Antibodies Ltd. (1997–2025)
Cash flow-to-debt ratio of ImmunoPrecise Antibodies Ltd. from 1997 to 2025. Historical debt coverage capacity for ImmunoPrecise Antibodies Ltd. across 29 annual periods. Check HYFT cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
ImmunoPrecise Antibodies Ltd. Cash Flow-to-Debt Ratio by Year (1997–2025)
ImmunoPrecise Antibodies Ltd. cash flow-to-debt ratio by year from 1997 to 2025. Year-by-year debt coverage analysis for ImmunoPrecise Antibodies Ltd.. For the full cash flow conversion analysis, see ImmunoPrecise Antibodies Ltd. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.31x | $-6.41 Million | $20.82 Million | ▼ -89.1% |
| 2024 | -0.16x | $-4.25 Million | $26.07 Million | ▲ +83.6% |
| 2023 | -0.99x | $-19.83 Million | $20.01 Million | ▼ -83.4% |
| 2022 | -0.54x | $-9.92 Million | $18.36 Million | ▼ -803.7% |
| 2021 | -0.06x | $-600.00K | $10.04 Million | ▲ +47.7% |
| 2020 | -0.11x | $-1.39 Million | $12.18 Million | ▲ +63.4% |
| 2019 | -0.31x | $-3.21 Million | $10.28 Million | ▼ -8.4% |
| 2018 | -0.29x | $-3.42 Million | $11.87 Million | ▲ +66.6% |
| 2017 | -0.86x | $-721.65K | $836.91K | ▼ -243.3% |
| 2016 | 0.60x | $284.09K | $472.15K | ▲ +524.3% |
| 2015 | -0.14x | $-36.11K | $254.64K | ▲ +7.7% |
| 2014 | -0.15x | $-46.60K | $303.50K | ▼ -840.9% |
| 2013 | -0.02x | $-4.33K | $265.63K | ▲ +97.4% |
| 2012 | -0.62x | $-132.72K | $213.10K | ▲ +34.0% |
| 2011 | -0.94x | $-80.39K | $85.19K | ▲ +69.3% |
| 2010 | -3.07x | $-308.49K | $100.47K | ▼ -197.5% |
| 2009 | -1.03x | $-155.68K | $150.84K | ▲ +92.6% |
| 2008 | -13.97x | $-523.45K | $37.46K | ▼ -632.5% |
| 2007 | -1.91x | $-297.31K | $155.85K | ▼ -139.1% |
| 2006 | -0.80x | $-110.59K | $138.62K | ▲ +54.2% |
| 2005 | -1.74x | $-82.20K | $47.18K | ▲ +51.3% |
| 2004 | -3.58x | $-178.69K | $49.92K | ▲ +65.9% |
| 2003 | -10.51x | $-168.38K | $16.02K | ▼ -604.0% |
| 2002 | -1.49x | $-280.23K | $187.72K | ▼ -16357.5% |
| 2001 | -0.01x | $-8.13K | $896.75K | ▲ +100.0% |
| 2000 | -20.63x | $-208.54K | $10.11K | ▼ -263.7% |
| 1999 | -5.67x | $-202.94K | $35.78K | ▼ -68.5% |
| 1998 | -3.37x | $-226.81K | $67.39K | ▼ -677.8% |
| 1997 | -0.43x | $-108.20K | $250.04K | — |